Janux Therapeutics
Novel immunotherapies that selectively modulate T cells for cancer and autoimmune disease treatment
- Sector
- Biotech
- Headquarters
- La Jolla, CA
- Founded
- 2017
- Latest Form D
- $125M, Apr 2021
- Total capital
- $192M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $192M
- 3 Form D · last Apr 2021
- 66 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 8
- 32 pending · first 2022
- Rank in peer group#196 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 3rd filing$125M
- Private capital raisedForm D · SEC · 2nd filing$56M
- Private capital raisedForm D · SEC · 1st filing$11.4M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#196 · top 14%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- David Campbell, Ph.D.Executive Officer, DirectorNamed in SEC Form D filings
- Jake Simson, Ph.D.DirectorNamed in SEC Form D filings
- Jay Lichter, Ph.D.DirectorNamed in SEC Form D filings
- Peter Thompson, M.D.DirectorNamed in SEC Form D filings
- Sheila GujrathiDirectorNamed in SEC Form D filings
- Stefan HellerDirectorNamed in SEC Form D filings
Show all 8 people
- Tighe ReardonExecutive OfficerNamed in SEC Form D filings
- Vickie L. CappsDirectorNamed in SEC Form D filings
What it has protected
USPTO · 8 granted of 40- PendingAntibodies For Targeting CD28 And Uses ThereofUSPTOApplication 19659950
- GrantedModified AntibodiesUSPTOUS 12,734,208
- GrantedTumor Activated Antibodies Targeting TROP2 And Uses ThereofUSPTOUS 12,723,099
Show all 40 patent records
- Antibodies For Targeting CD28 And Uses ThereofSep 17, 2026 · Application 19659950Pending
- Modified AntibodiesSep 15, 2026 · US 12,734,208Granted
- Tumor Activated Antibodies Targeting TROP2 And Uses ThereofSep 1, 2026 · US 12,723,099Granted
- Antibodies For Targeting Psma And CD28 And Uses ThereofAug 20, 2026 · Application 19659963Pending
- T Cell Engagers And Methods Of Use ThereofAug 13, 2026 · Application 19652551Pending
- Multispecific Polypeptides And Methods Of Use ThereofAug 6, 2026 · Application 19652533Pending
- Compositions And Methods Related To Tumor Activated Molecules Targeting NECTIN-4 And Effector Cell AntigensAug 6, 2026 · Application 19419529Pending
- Antibodies Targeting STEAP-1 And Uses ThereofJul 30, 2026 · Application 19639514Pending
- Compositions And Methods Related To Tumor Activated Antibodies Targeting Psma And Effector Cell AntigensJul 30, 2026 · Application 19570589Pending
- Antibodies Targeting STEAP-1 And CD3 And Uses ThereofJul 30, 2026 · Application 19639601Pending
- Compositions And Methods Related To Tumor Activated Antibodies Targeting Psma And Effector Cell AntigensMay 14, 2026 · Application 19444725Pending
- Compositions And Methods Related To Tumor Activated Antibodies Targeting Psma And Effector Cell AntigensMay 5, 2026 · US 12,617,865Granted
- Inhibitory T Cell Receptor Peptides And Discovery MethodsApr 21, 2026 · US 12,606,816Granted
- Optimized Antibodies Targeting CD3 And Uses ThereofFeb 19, 2026 · Application 19297880Pending
- Tumor Activated Antibodies Targeting CD3 And Uses ThereofFeb 19, 2026 · Application 19374607Pending
- Compositions And Methods Related To Tumor Activated Antibodies Targeting Egfr And Effector Cell AntigensJan 15, 2026 · Application 19327021Pending
- Compositions And Methods Related To Tumor Activated Antibodies Targeting Psma And Effector Cell AntigensJan 1, 2026 · Application 19320207Pending
- Compositions And Methods Related To Tumor Activated Antibodies Targeting Egfr And Effector Cell AntigensOct 7, 2025 · US 12,433,953Granted
- Compositions And Uses Of Tumor Activated Antibodies Targeting Egfr And Effector Cell AntigensSep 25, 2025 · Application 19187587Pending
- Antibodies Targeting Egfr And CD3 And Uses ThereofAug 7, 2025 · Application 19187324Pending
- Optimized Antibodies Targeting TROP2 And Uses ThereofMay 15, 2025 · Application 18840196Pending
- Cleavable Linker Compositions And MethodsJan 16, 2025 · Application 18890543Pending
- Compositions And Methods Related To Tumor Activated Antibodies Targeting Egfr And Effector Cell AntigensDec 10, 2024 · US 12,161,724Granted
- Compositions And Methods Relating To Tumor Activated T Cell EngagersNov 14, 2024 · Application 18785900Pending
- Antibodies Targeting Egfr And CD3 And Uses ThereofAug 1, 2024 · Application 18559179Pending
- Antibodies Targeting TROP2 And CD3 And Uses ThereofMar 21, 2024 · Application 18041876Pending
- Compositions And Methods Related To Tumor Activated Antibodies Targeting Psma And Effector Cell AntigensFeb 22, 2024 · Application 18314077Pending
- Antibodies Targeting Psma And CD3 And Uses ThereofFeb 8, 2024 · Application 18031724Pending
- Peptide Compositions And Methods For ANTI-CD3 Binding DomainsFeb 8, 2024 · Application 18256278Pending
- Compositions And Methods Related To Tumor Activated Antibodies Targeting TROP2 And Effector Cell AntigensFeb 1, 2024 · Application 18256271Pending
- Single Domain Anti-Albumin AntibodyFeb 1, 2024 · Application 18256276Pending
- Multispecific Antibodies For Targeting CD28 And PD-L1 And Methods Of Use ThereofDec 21, 2023 · Application 18249886Pending
- Antibodies Targeting HER2 And CD3 And Uses ThereofDec 21, 2023 · Application 18249879Pending
- Tumor Activated Multispecific Antibodies For Targeting CD28 And PD-L1 And Methods Of Use ThereofNov 9, 2023 · Application 18314090Pending
- Tumor Activated T Cell Engagers And Methods Of Use ThereofJul 13, 2023 · Application 17616278Pending
- Compositions And Methods Relating To Tumor Activated T Cell EngagersJul 13, 2023 · Application 17616281Pending
- Cleavable Linker Compositions And MethodsMay 11, 2023 · Application 17972348Pending
- Compositions And Methods Related To Tumor Activated Antibodies Targeting Psma And Effector Cell AntigensJan 17, 2023 · US 11,555,078Granted
- Cleavable Linker Compositions And MethodsNov 29, 2022 · US 11,512,113Granted
- Modified T Cell ReceptorsApr 22, 2021 · Application 16769536Pending
Related companies, and why
- Bright Peak TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Cognito Therapeutics Group, Inc.Similar federal contract value in Biotech · null in contracts
- BioAge LabsSimilar federal contract value in Biotech · null in contracts
- NewLimit, Inc.Similar federal contract value in Biotech · null in contracts
- GondolaBioSimilar federal contract value in Biotech · null in contracts
- BIOHARVEST SCIENCES INC.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .